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Summary
 
We describe here a new subset of T cells, found in humans, mice, and cattle. These cells bear a
canonical T cell receptor (TCR) 
 
a
 
 chain containing hAV7S2 and AJ33 in humans and the ho-
mologous AV19-AJ33 in mice and cattle with a CDR3 of constant length. These T cells are
CD4
 
2
 
CD8
 
2
 
 double-negative (DN) T cells in the three species and also CD8
 
aa
 
 in humans. In
humans, their frequency was 
 
z
 
1/10 in DN, 1/50 in CD8
 
a
 
1
 
, and 1/6,000 in CD4
 
1
 
 lympho-
cytes, and they display an activated/memory phenotype (CD45RA
 
lo
 
CD45RO
 
1
 
). They prefer-
entially use hBV2S1 and hBV13 segments and have an oligoclonal V
 
b
 
 repertoire suggesting
peripheral expansions. These cells were present in major histocompatibility complex (MHC)
class II– and transporter associated with antigen processing (TAP)-deficient humans and mice
and also in classical MHC class I– and CD1-deficient mice but were absent from 
 
b
 
2-microglo-
bulin–deficient mice, indicating their probable selection by a nonclassical MHC class Ib mole-
cule distinct from CD1. The conservation between mammalian species, the abundance, and
the unique selection pattern suggest an important role for cells using this novel canonical TCR
 
a
 
 chain.
Key words: invariant T cell receptor 
 
a
 
 chain • CD4
 
2
 
CD8
 
2
 
 T cells • humans • cattle • mice
 
B
 
and T lymphocytes display a wide repertoire of antigen
receptors, made by random recombination of V, (D),
and J segments and trimming/addition of nucleotides at the
junctions between these rearranged segments (1). Besides the
mainstream lymphocytes, three different types of cell sub-
populations have been described that have a limited reper-
toire diversity: the B1 B cell subset (2, 3), some 
 
g
 
/
 
d
 
 T cell
subpopulations (4), and the TCR 
 
a
 
/
 
b
 
1
 
 NK1 T cells (5).
Restricted repertoires seem to define discrete lymphocyte
subpopulations at the frontier between innate and adaptive
immunity, as these selected repertoires may allow the pres-
ence of a high frequency of preexisting cells reactive against
phylogenetically conserved antigens (6, 7). Alternatively,
cells with such a restricted repertoire may play an immuno-
regulatory role or another physiologic function, such as the
wound healing, that results from the secretion of keratino-
cyte growth factor (8) by 
 
g
 
/
 
d
 
 dendritic epithelial cells
(DECs)
 
1
 
 recognizing self-ligands (9).
B1 cells, which appear early during embryonic life, use
recurrent VDJ combinations with few “N” additions (10),
and seem to be selected by endogenous ligands (11). Simi-
larly, some 
 
g
 
/
 
d
 
 T cell subsets appear early during ontogeny
and use peculiar V-J combinations without N additions
(12). These recurrent sequences seem to be favored by en-
zymatic constraints linked to the recombination process,
such as homologous region–guided recombination (4).
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Abbreviations used in this paper:
 
 APC, allophycocyanin; 
 
b
 
2m, 
 
b
 
2-micro-
globulin; B6, C57BL/6; DEC, dendritic epithelial cell; DN, CD4
 
2
 
CD8
 
2
 
double-negative; IEL, intraepithelial lymphocyte; TAP, transporter asso-
ciated with antigen processing; TC, Tricolor. 
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Cells bearing these invariant 
 
g
 
/
 
d
 
 TCRs seem to be also se-
lected by endogenous ligands as, in mice deficient for these
segments, they are replaced by cells expressing other V
 
g
 
V
 
d
 
combinations but similar clonotypic motifs (13).
NK1 T cells use an “invariant” 
 
a
 
 chain (mAV14AJ18 in
mice [14], hAV24AJ18 in humans [14, 15]) with a CDR3
of constant length paired with a limited number of V
 
b
 
 seg-
ments (BV2S1, 7S1, and 8S2 in mice, BV11S1 in humans).
NK1 T cells display peculiar phenotypic characteristics:
they are CD3
 
int
 
, CD4
 
1
 
, or CD4
 
2
 
CD8
 
2
 
 (DN), and have
both activation (CD44
 
hi
 
 and 3G11
 
lo
 
) and NK markers
(NKRP1, Ly49) (5). In vivo development of NK1 T cells
requires the MHC class Ib CD1d molecule (16), whose ex-
pression is 
 
b
 
2-microglobulin (
 
b
 
2m) dependent but trans-
porter associated with antigen processing (TAP) indepen-
dent (17). In both humans and rodents, mature NK1 T
cells recognize some glycolipids (such as 
 
a
 
-galactosylcera-
mide) in a CD1d-restricted fashion (18, 19) as well as some
exogenous protozoan glycosylphosphatidylinositol (GPI
[20]), but the exact endogenous ligand(s) presented physio-
logically by CD1d have not yet been identified. The most
salient feature of NK1 T cells is their ability to secrete very
rapidly large amounts of IL-4 in a primary response (21).
They can also secrete large amounts of IFN-
 
g
 
, especially
when triggered through their NKRP1 receptor (22). How-
ever, their true in vivo functions are still enigmatic, though
there is evidence that they may be involved in Th1/Th2
class polarization (23), in IL-12–induced tumor rejection
(24), and in autoimmunity (25–27).
Mainstream 
 
a
 
/
 
b
 
 T lymphocytes express either CD8 or
CD4 accessory molecules and respond to peptidic antigens
presented in low amounts by either MHC class I or class II
molecules. The absence of accessory molecules in the DN
T cell subpopulation suggests that these cells may recognize
high-density ligands (such as 
 
a
 
-galactosylceramide or glyco-
sylphosphatidylinositol presented by CD1 for NK1 T cells)
and/or display TCRs with high affinity. Indeed, most 
 
g
 
/
 
d
 
T cells are DN or CD8
 
aa
 
, and the NK1 T cells comprise
both DN (and CD8
 
aa
 
1
 
 in humans [28]) and CD4
 
1
 
 
 
cells,
though the CD4 molecule in these latter does not seem to
play a role in the binding affinity (14, 29). DN 
 
a
 
/
 
b
 
1
 
 T cells
represent between 0.5 and 2% of PBLs in normal individu-
als and comprise the aforementioned NK1 T cells and other
cells of unclear specificity or functions. Some of these also
recognize CD1d, while others are specific for glycolipids
presented by CD1a, b, or c (30–32).
NK1 T cells thus far represent the only known T cell
subset that has conserved its TCR, its specificity, and its
functional features between rodents and primates, suggest-
ing that they may play an ancient and important physiolog-
ical role (18). Here, we report on the existence of another
phylogenetically conserved population of T cells in mam-
mals, defined by the expression of a novel canonical TCR
 
a
 
 chain comprising the hAV7S2 and AJ33 elements in hu-
mans and the homologous AV19 and AJ33 elements in
mice and cattle. V
 
a
 
7/19-J
 
a
 
33
 
1
 
 T cells show an oligoclonal
TCR 
 
b
 
 chain repertoire and are selected by a 
 
b
 
2m-depen-
dent but TAP-independent molecule that is neither a clas-
sical MHC class I molecule nor CD1d. The conservation
between species of T cells displaying this limited repertoire
and their unusual restriction pattern suggest that this popu-
lation may serve a function complementary to that played
by NK1 T cells.
 
Materials and Methods
 
Antibodies.
 
In humans, the following antibodies, anti-CD28–
PE, anti-CD45RA–PE, anti-CD45RO–PE, anti-CD57–FITC,
anti-CD56–PE, anti-
 
a
 
/
 
b
 
 TCR–allophycocyanin (APC), anti-
 
a
 
/
 
b
 
TCR–PE, anti-CD8
 
b
 
–PE, biotinylated anti-CD4, and anti-
CD8
 
a
 
, were obtained from Immunotech; anti-CD27–FITC and
anti-
 
a
 
/
 
b 
 
TCR–FITC were purchased from PharMingen. Anti-
CD8
 
a
 
–FITC and –Tricolor (TC), anti-CD4–FITC and –PE,
and anti-CD3–TC were obtained from Caltag Laboratories. An
anti-CD4–FITC (Diaclone) recognizing an epitope distinct from
the anti-CD4 magnetic beads was also used. Streptavidin–Red
613 was purchased from GIBCO BRL. Streptavidin-PE and -TC
were obtained from Caltag Laboratories.
In mice, anti-CD4 (RM4-5 or RM4-4)–PE, anti-CD8
 
a
 
– or
anti-CD8
 
b
 
–FITC, biotinylated or Cychrome-conjugated anti-
 
a
 
/
 
b
 
 TCR and streptavidin-APC were obtained from PharMin-
gen. Anti-
 
a
 
/
 
b
 
 TCR–TC was obtained from Caltag Laboratories.
Bovine anti-CD4 and anti-CD8
 
a
 
 antibodies were provided by J.
Naessens, International Laboratory for Research on Animal Dis-
eases (ILRAD, Nairobi, Kenya).
 
Human Cell Preparations.
 
Heparinized blood was obtained from
healthy donors or from MHC-deficient patients, and PBMCs were
purified by Ficoll-Hypaque (Amersham Pharmacia Biotech) gradi-
ent centrifugation. Cells were frozen in liquid nitrogen until use.
 
Bovine Cell Separations.
 
Bovine blood was provided by Mr.
Noé from the GENA Laboratory, Institut National de la Recher-
che Agronomique (INRA, Jouy en Josas, France). After Ficoll-
Hypaque separation, PBLs were labeled with anti-CD4 and/or
anti-CD8 (both Ig2a), which were revealed with an FITC-con-
jugated goat anti-Ig2a serum. Cells were FACS
 
®
 
 sorted into CD4
or CD4/CD8 positive or negative fractions as indicated, and the
relative amounts of boC
 
a
 
- or boAV19-boAJ33 transcripts were
estimated by kinetic PCR (see below).
 
Mice.
 
C57BL/6 (H-2
 
b
 
) (B6), BALB/c (H-2
 
d
 
), 129 (H-2
 
b
 
),
DBA/2 (H-2
 
d
 
), and CBA (H-2
 
k
 
) mice were bred in our own
specific pathogen–free animal facility. 
 
b
 
2m2/2 and I-Ab2/2 mice,
backcrossed nine times to B6, were obtained from the Centre
National de la Recherche Scientifique central animal facility
(CNRS, Orleans, France). TAP2/2 B6/129 and CD82/2 defi-
cient mice were obtained from The Jackson Laboratory. Kb2/2
Db2/2 mice have been described (33). CD12/2 mice were gener-
ated by S.-H. Park and A. Bendelac (unpublished results).
Immunofluorescence Studies. Surface phenotyping was carried
out on a FACSCalibur™ cytometer (Becton Dickinson). Three-
color sorting (CD4, CD8a, and a/b TCR staining) was carried
out on a FACS Vantage™ (Becton Dickinson) to obtain a/b1
DN, -CD8a1, or -CD41 cells. Reanalyzed fractions were .99%
pure. In some experiments, DN cells were seeded into 96-well
PCR microplates at the indicated cell concentrations using a sin-
gle cell deposition unit (Becton Dickinson). DN/CD81 fractions,
enriched or depleted for a given marker, were obtained by
FACS® sorting negative and positive fractions for this marker af-
ter quadruple staining with anti-CD4, anti-CD8a, anti-a/b TCR,
and the relevant marker (either CD8b, CD45RA, CD45R0,
CD56, CD57, CD28, or CD27).
In some experiments, DN and CD8a1 enriched fractions were1909 Tilloy et al.
obtained using paramagnetic beads and the VarioMacs system
(Miltenyi Biotec). In brief, cells at 107/100 ml were resuspended
in PBS, 0.5% BSA, 5 mM EDTA and incubated with anti-CD4
paramagnetic microbeads, washed once, resuspended in 500 ml of
the same buffer, and passed through an RS column. Effluent was
collected as the DN1CD81 fraction. After thorough washes of
the column, the eluate was collected as CD41 fraction. In these
conditions, the CD41 fraction was .95% pure.
Oligonucleotides. All primers and probes were obtained from
Genosys Biotechnologies and used without further purification.
Probes were FITC conjugated. The following primers have been
described previously (14): mAV14, mAJ18, mAC-59, mACV,
mAC-39, hACV, hAC-59, and hAC-39. The following primers
were used (m, bo, and h stand for murine, bovine, and human;
p is for probe; in and out are for the inner and outer primer, re-
spectively, in the case of nested PCR): mAV19, CACTTTCCT-
GAGCCGCTCGAA; mAJ33, biotin-TTAGCTTGGTCCCA-
GAGCCCC; pmAV19, GCTTCTGACAGAGCTCCAG-FITC.
The mouse-specific Vb and Va primers were slightly modified
from Casanova et al. (34). The human Vb primers were derived
from Puisieux et al. (35) as modified by Martinon et al. (36). The
other human primers were as follows: hAV7S2, biotin-CCT-
TAGTCGGTCTAAAGGGTACAG; hAJ33, CCCAGCGCCC-
CAGATTAA; hBJ1S2, GTCTCCCTCAGTCTGGCTCCG;
hBJ1S3in, GGTGGTAAGGTCAGAGGCTCTTTTATC; hBJ1S3-
out, TCTGTGTGAGGGAGAGAAACG; hBJ1S5, CAAGACAC-
ACCAAAGGGAACGC; hBJ2S2, CTCTCCCAGCACCCAGA-
ACCA; hBJ2S4, CGCACAAAAACCCGAGCGCAG; hBJ1S6in,
CCAGGCACCCCCGAGTCAAGA; hBJ1S6out, GGCAACA-
CAGCAGAGCAACAA; hBJ2S7out, TCGTCCTCTCCAGT-
CTCGCCT; hBJ2S7in, CGCCCTCTGCTCAGCTTTCCG;
and hAJ33in, CAAAAGCTGACTTGCAGGCATCG. In cattle,
the following primers were used: boAV19, biotin-CATTCCTTA-
GACGCTCTGATGCACA; boAJ33, GCCCCAGATCCACT-
GATAGTTGC; pboAV19, FITC-GTGGAGTTCCTTCAGAAG-
GAG; bo59CA, biotin-AGGACCCCAACCCCACTGTGT;
bo39CA, CTTCAGGAGGAGGATGCGGAAC; and pboCA,
FITC-CACTGGATTGGGGGCTTC.
Nucleic Acid Preparation. Genomic DNA was obtained as
crude cell lysate by adding to the cell pellets (1–106 cells) a solu-
tion containing 200 mg/ml proteinase K (Promega Corp.), 0.5%
Tween 20 (Sigma-Aldrich), 10 mM Tris-HCl, pH 9, 50 mM
KCl, 2.5 mM MgCl2. After resuspension, this solution was incu-
bated for 2 h at 568C, and the proteinase K was denatured by in-
cubation at 958C for 20 min.
Total RNA was extracted from 1–5 3 105 cells with the
RNAble solution (Eurobio), ethanol precipitated with addition of
2 ml Pellet Paint coprecipitant (Novagen), and resuspended in 20
ml sterile water. Reverse transcription was carried out as de-
scribed with random hexamers and oligo-dT priming (37).
Quantitative Kinetic PCR. Quantitative kinetic ELISA PCR
was carried out as described (37). Polyclonal samples were di-
vided into two aliquots before RNA extraction except in a few
instances in which the amount of sorted cells was too low (,2 3
104). Average values are shown.
In the most recent experiments, an ABI prism 7700 (Perkin-
Elmer) apparatus was used instead of the ELISA assay to monitor
the amount of amplicon during the PCRs. This apparatus is based
on the 59 to 39 nuclease activity of Taq polymerase (38), which
allows the release of a fluorescent reporter during the PCR. A
probe labeled with both a reporter and a quencher dye is spiked
into the PCR mix at the beginning of the reaction. The se-
quences of the Taqman probes used in this study are the fol-
lowing: hCA, mGCATGTGCAAACGCCTTCAACAACAqp;
hAV7.2, mTGAAAGACTCTGCCTCTTACCTCTGTGCqp;
mAC, mCTCCCAAATCAATGTGCCGAAAACCAqp; mAV19,
mTCCAGATCAAAGACTCTGCCTCATACCTCTGqp; and
mAV14, mCACCCTGCTGGATGACACTGCCACqp; where
m preceding each sequence stands for FAM and qp following for
TAMRA blocked with a phosphate. When using the ABI prism
7700 apparatus, the following primers were also used: hAV7S2,
TCCTTAGTCGGTCTAAAGGGTACAG; hAJ33, CCAGCG-
CCCCAGATTAA; hAC-59, ACCCTGACCCTGCCGTGT;
hAC-39, GGCTGGGGAAGAAGGTGTCTT; mAV14, TGG-
GAGATACTCAGCAACTCTGG; mAJ18, CCAGCTCCAA-
AATGCAGCC; mAV19, CTTTCCTGAGCCGCTCGAA;
mAJ33, CTTGGTCCCAGAGCCCC; mAC-59, CCTCTGC-
CTGTTCACCGACTT; and mAC-39, CGGTCAACGTGGC-
ATCACA. In these quantitative kinetic PCR methods, for two
samples containing the same amount of Ca, a shift of n cycles
along the x-axis of the two amplification curves represents an
z1.8n-fold difference in the two samples studied.
Single Cell Repertoire Analysis. Single human DN a/b T cells
were sorted into 84 wells of PCR plate. 11 of the remaining wells
were used as negative controls and 1 as positive. After cell lysis,
PCR amplification was carried out for 25 cycles using the follow-
ing primers: 29 Vb, 7 Jb, AV7S2out, AJ33out, and as positive
control AV24 and AJ18out. The resulting reaction mix was di-
luted fivefold, and aliquots were amplified in a second PCR reac-
tion with an AV7S2/AJ33 primer pair for 40 cycles. The specific
AV7S2-AJ33 amplicons were detected by ELISA or using the
Taqman assay. Aliquots of the AV7S2-AJ33–positive wells from
the first PCR reaction were then PCR amplified in 24 individual
PCR reactions with 1 (or 2) specific Vb primer(s) and a mixture
of 7 Jb primers for 45 cycles. The positive reactions were de-
tected by agarose gel electrophoresis, and the amplicons were se-
quenced as described below.
Sequencing. Polyclonal sequencing was performed after am-
plification for 42 cycles with hAV7S2, boAV19, or mAV19 and
either AJ33 or Ca primer pairs. The amplicons were purified us-
ing the Wizard PCR clean-up system (Promega Corp.) and se-
quenced using either a nested primer in the Ca constant region
(in mouse) or the same AV19 or AV7S2 primer as used for ampli-
fication, as appropriate. Sequences were performed with the
Thermosequenase radiolabeled terminator cycle sequencing kit
(Amersham Pharmacia Biotech) with 33P-ddNTP.
T–T Hybridoma Generation. DN and CD81 T cells were
obtained from TAP2/2 mice after depleting CD41 T cells with
anti-CD4 antibody (GK1.5 and 172.4) plus rabbit complement
(Behring AG) followed by centrifugation over a density gradient
(Lympholyte M; Cedarlane Laboratories). 2 3 106 cells were stim-
ulated, in the presence of 4 3 106 g-irradiated (2,500 cGy) splenic
cells, for 2 d with soluble anti-a/b TCR (H57) at 7.5 mg/ml
which had been precoated for 1 h at 378C in flat-bottomed
96-well plates. Cells were cultured for an additional 2 d with
IL-2 (100 U/ml) in complete culture medium: RPMI 1640, 15%
FCS, 2 mM l-glutamine (GIBCO BRL), penicillin 100 U/ml,
streptomycin 100 mg/ml, 50 mM b-ME. At day 4, 8 3 106 cells
were fused with 2.5 3 107 TCR a/b2 BW5147 thymoma cells
using standard procedures, plated at 4 3 104 cells per well in
96-well microplates, and selected in HAT medium. Resulting
clones were screened for expression of AV19-AJ33 rearrange-
ment on genomic DNA followed by sequencing. Vb were char-
acterized by 17 Vb-specific PCR reactions, and the resulting
amplicons were then sequenced. Results were verified by immu-
nofluorescence with specific anti-Vb antibodies.1910 A Novel T Cell Subpopulation in Mammals
Results
A previous analysis of TCR a chain repertoire of human
DN T cells indicated that besides the invariant hAV24AJ18
TCR a chain, another TCR a chain was frequently ex-
pressed that also had a restricted AVAJ usage and recurrent
junctional features (39). This a chain, which was encoded by
rearranged hAV7S2AJ33 elements, had a CDR3 of constant
length but some variability in the two junctional codons. A
GenBank search showed that among the 20 TCR a chains
sequenced in cattle, one chain (BOTCRA14) used the ho-
mologous Va and Ja segments with a CDR3 of the same
length (40). In mice, no homologous invariant a chain had
been described, but the corresponding Va (mAV19) and Ja
(mAJ33) segments display high homology with their hu-
man counterparts, as there is only one amino acid differ-
ence between the murine AJ33 and its human counterpart
(41, 42). Based on these observations, which suggested the
existence of another conserved T cell population in mam-
mals, we undertook an extensive analysis of the frequency
and repertoire of the T cells bearing this particular combi-
nation of AVAJ elements in these three species. 
Canonical hAV7S2AJ33 TCR a Chains, as well as Their 
Murine and Bovine Homologues, Are Abundantly Expressed in 
DN T Cells
Homologous hAV7S2AJ33 or bo/mAV19AJ33 Transcripts
Are Enriched in Human, Bovine, and Murine DN T Cells.
To determine the frequency and coreceptor phenotype of
T cells bearing hAV7S2AJ33 TCR a chains, PBLs were
separated into highly purified a/b DN, CD41, or CD8a1
(i.e., CD8aa1 and CD8ab1) subsets, and the amount of
hAV7S2AJ33-encoded transcripts in duplicate fractions was
quantified by kinetic PCR. Although the amounts of Ca
chain were similar in all samples (Fig. 1 A), there was a
large shift to the left of the hAV7S2AJ33 amplification
curves for the DN (8.5 cycles) and the CD8a1 fractions
(5 cycles) (Fig. 1 B) compared with the CD41 fractions, in-
dicating that DN and CD8a1 cells contained z150–360-
and 19–32-fold more hAV7S2AJ33 transcripts, respec-
tively, than CD41 lymphocytes. hAV7S2AJ33 transcripts
were enriched in DN and CD8a1 T cell preparations from
all individuals tested, and on average the enrichment levels
of hAV7S2AJ33 transcripts in DN T cells were much
higher than those observed for the NK1 T cell–specific in-
variant a chain hAV24AJ18 (data not shown).
Because a similar invariant a chain had been sequenced
once in cattle (40), we examined its distribution within
CD41, CD81, DN, or (CD41 plus CD8a1) sorted cells ob-
tained from bovine blood. As shown in Fig. 1, C and D, the
levels of boAV19AJ33 transcripts in the DN fractions were as
high as those observed in humans. No boAV19AJ33 ampli-
fication could be obtained with the CD8a1 fraction, and
the comparison of CD41 and CD41 plus CD8a1 amplifi-
cation curves suggested that bovine CD8a1 cells did not
express high amounts of boAV19AJ33 transcripts.
In mice, no canonical TCR a chain rearrangement involv-
ing mAV19 and mAJ33, the murine elements that are homol-
ogous to hAV7S2 and hAJ33, respectively, had been de-
scribed. However, quantitative PCR analysis of mAV19AJ33
transcripts within highly purified murine a/b DN, CD41,
and CD8a1 lymphocytes indicated that, as in human and
bovine blood, increased mAV19AJ33 expression was ob-
served in the DN fraction from lymph nodes (Fig. 1, E and
F). The shift of the amplification curves between DN and
CD41 cell preparations was lower than in humans and cattle,
Figure 1. High levels of hAV7S2/AV19-AJ33 TCR a chain are
present in DN T cells from three mammal species: the indicated cell sub-
populations were purified by FACS® sorting from human (A and B) or
bovine (C and D) PBLs and from mouse lymph nodes (E and F). Dupli-
cate RNA preparations were obtained and, after reverse transcription,
PCR was carried out for the indicated gene segments. The amount of
amplicon was quantified by ELISA at the indicated cycle. Averaged values
of duplicates are shown for C–F. CD8a1 fraction contains both CD8aa1
and CD8ab1 TCR a/b1 T cells. In cattle, no amplification could be ob-
tained with boAV19-AJ33 primers in the CD8a1 fraction, and thus the
corresponding curves are not displayed.1911 Tilloy et al.
suggesting that mAV19AJ33-bearing cells were less abundant
in mice.
hAV7S2-AJ33, mAV19AJ33, and boAV19AJ33 Transcripts
Display the Same CDR3 Length in the Three Species. To ex-
amine the length of the CDR3 regions of the hAV7S2AJ33
transcripts and their homologues in mice and cattle, we
carried out polyclonal sequencing of Va-Ca or Va-Ja am-
plicons obtained from the various lymphocyte subpopula-
tions in these species. As shown in Fig. 2 A, a readable
hAV7S2AJ33 sequence was obtained from hAV7S2-Ca
amplicons derived from DN and CD8a1 samples but not
from CD41 samples. Therefore, this indicated that in the
former but not the latter cells, the hAV7S2 segment was pre-
dominantly rearranged to the hAJ33 segment and comprised
a CDR3 of constant length. The polyclonal hAV7S2AJ33
sequence displayed some heterogeneity at the VJ junction,
in agreement with previous results from Porcelli et al.
showing some variability of the two N-encoded amino ac-
ids (39).
In cattle, the picture was slightly different, as polyclonal
sequencing of boAV19-Ca amplicons demonstrated the
predominant presence of the invariant boAV19AJ33 chain
in DN cells, but not in CD41 or CD81 cells (data not
shown). At the VJ junction, the polyclonal sequence de-
rived from DN cells displayed some junctional heterogene-
ity, indicating also some variability of the two amino acids
encoded by N additions. In mice, polyclonal sequencing of
the mAV19-Ca amplicons showed a fully readable se-
quence for the DN but not for the CD8a1 fraction (data
not shown). Moreover, the VJ sequence displayed no het-
erogeneity and corresponded to a “germline” junction
without nucleotide trimming or N addition (see also Table
Figure 2. (A) The CDR3 of
hAV7S2-AJ33 TCR a chain is of
constant length in DN T cells and
in human CD8aa1 T cells. PCR
amplifications from hAV7S2 to
Ca (V-C) or to AJ33 (V-J) were
carried out on cDNA from the T
cell subpopulations indicated, and
polyclonal sequencing was carried
out using the same AV7S2/AV19
primer as used for amplifica-
tion.  Panel B displays polyclonal
sequencing of FACS®-sorted
CD8ab1 or CD8aa1 TCR
a/b1 human PBLs.
Figure 3. High homology of human, cattle, and mouse hAV7S2/AV19-AJ33 a chains. Homologies were scored using the default PAM250 of ClustalW
as implemented in MacVector software (Oxford Technology). Identities are bold and shaded in gray; similarities are light gray. The CDR3 region is boxed.1912 A Novel T Cell Subpopulation in Mammals
II below). Altogether, these results demonstrated that in the
three species, DN a/b1 T cells were enriched for cells bear-
ing TCR a chains with highly homologous AVAJ elements
(hAV7S2AJ33, mAV19AJ33, and boAV19AJ33) and constant
CDR3 length as shown in the multiple alignment displayed
in Fig. 3. This novel canonical TCR a chain will be referred
to hereafter as the “invariant” Va7/19-Ja33 TCR a chain.
Direct Numbering of Cells Bearing Invariant Va7/19-Ja33
Chains. A large amount of invariant a chain transcripts
does not formally demonstrate the existence of a large
number of invariant TCR a chain–bearing cells, as this
transcript could have been expressed at very high levels in a
few cells. To more directly estimate the number of cells us-
ing the invariant Va7-Ja33 chain, single a/b1 DN cells
from three different subjects were sorted into PCR plates
using a single cell deposition unit. FACS®-sorted  a/b1
TCR CD8a1 or CD41 cell suspensions were also serially
diluted into PCR plates to get 12 replicates of the indicated
cell concentrations. After cell lysis, hAV7S2AJ33 PCR am-
plification was carried out on genomic DNA with lumi-
nometry detection of the amplicons. As shown in Fig. 4 A,
the assay was sensitive enough to detect a single cell har-
boring the relevant rearrangement and yielded a frequency
of Va7-Ja331 DN cells of z1/7.4. Using limiting dilution
analysis (LDA), the frequency observed for CD8a1 cells
was 1/36 (confidence interval: 1/25–1/70; Fig. 4 B). Se-
quence analysis of amplicons from single cell preparations
obtained with DN and CD8a1 cells demonstrated the pres-
ence of invariant Va7-Ja33 transcripts in all cases. A similar
analysis on CD41 cells yielded a frequency of Va7-Ja331
cells of 1/1,093 (1/751–1/2,003; Fig. 4 C). Importantly,
sequencing of the positive wells at concentrations where
the Va7-Ja33 amplicons were derived from one cell showed
that out of six positive wells, two corresponded to a rear-
rangement of the hAV7S2 to hAJ34 (which were amplified
because of the short genomic distance [z700 bp] separating
hAJ34 from hAJ33), three corresponded to a rearranged
Va7-Ja33 chain with a different CDR3 length, and only
one corresponded to the invariant Va7-Ja33 chain. Thus,
the actual frequency of CD41 cells harboring the invariant
Va7-Ja33 chain should be z1/6,000.
In mice, Va19-Ja331 cells were less numerous than in
humans. Their frequency within a/b DN lymph node
cells was 1/56 (Fig. 5 A), compared with z1/7.5 in hu-
mans (Fig. 4 A).
Surface Phenotype and TCR b Repertoire of
Va7/19-Ja33–bearing Cells
Invariant Va7-Ja33–bearing Cells Express Memory Markers
and Show a Biased Usage of hBV2 and hBV13 TCR b Chains.
In the absence of anti-hAV7S2 or anti-mAV19 antibody,
we used the following strategy to characterize the surface
phenotype of the population expressing the invariant Va7-
Ja33 chain. a/b DN and CD8a1 cells were depleted or
enriched for a given marker by FACS® sorting, and the
amounts of Va7-Ja33 transcripts in the positive and nega-
tive fractions were quantified and compared with the
amounts of amplified Ca transcripts, in order to take into
Figure 4. Direct enumeration of AV7S2/AV19-AJ33–bearing cells by
PCR–limiting dilution analysis and single cell PCR. (A) DN cells ob-
tained from three human subjects were seeded into microtiter plates using
a FACS® single cell deposition unit. After cell lysis, PCR was carried out
with AV7S2 and AJ33 primers, and the amount of amplicons was quanti-
fied by ELISA. (B and C) a/b CD8a1 or CD41 cells were obtained by
FACS® sorting, serially diluted, distributed in a microtiter plate at the in-
dicated cell concentration, and processed as above. In C (CD41 cells), the
amplicons of the six wells indicated (which had a high probability of
clonality) were sequenced. The sequences were as follows:
1-GCT GTG ATG TCG AT
2-GCT GTG AGA GAG ATC GGA
3-GCT GTG AGA GAT
4-GCT GNN ACT CGA
5-GCT GTG AGA GAG GAT AAC-AJ34-intron-AJ33
6-GCT GTG AGG GGG GGG GAA AAC-AJ34-intron-AJ33
Only one (sequence 3) corresponds to the canonical AV7S2-AJ33 rear-
rangement (see text for details). In B and C, frequencies were calculated
by maximum likelihood analysis.1913 Tilloy et al.
account variations in cell number. Fig. 6 displays an exam-
ple of such an experiment, where we examined whether
the CD8 molecules expressed by Va7-Ja331 cells were ei-
ther heterodimeric (ab) or homodimeric (aa), since
CD8aa1 cells represent between 5 and 25% of CD8a1
TCR a/b1 lymphocytes in human PBLs (data not shown).
There were z45-fold more Va7-Ja33 transcripts in the
CD8aa1 fraction than in the CD8ab1 fraction. This result
was confirmed by polyclonal sequencing of the amplicons
obtained after amplification with hAV7S2/Ca (V-C) or
hAV7S2/hAJ33 (V-J) primers: no readable sequence was
obtained from the CD8ab1 fraction, whereas the invariant
a chain was present in the CD8aa1 fraction (Fig. 2 B).
The absence of a readable sequence in the CD8ab1 frac-
tion using V-J amplification indicates the near absence of
the invariant a chain in this fraction. Using this strategy, it
could be established that Va7-Ja331 cells had mainly a
memory phenotype (i.e., CD45R01CD45RA2) and were
CD562CD572CD281CD271 (data not shown).
Despite many attempts using different lymphokine mix-
tures, we were unable to obtain a large enough number of T
cell clones expressing the invariant Va7-Ja33 chain. There-
fore, the TCR b chain repertoire of DN cells bearing invari-
ant Va7-Ja33 chain was directly estimated by single cell
PCR analysis. After single cell deposition of DN a/b cells
into PCR plates, cells were lysed and a first PCR reaction
was carried out using hAV7S2, hAJ33, and a mixture of 29
Vb and 7 Jb. This first reaction was then amplified in a sec-
ond PCR with nested AV7S2/AJ33 primers allowing us to
find the wells containing Va7-Ja331 cells. Using the reac-
tion mixture of the first PCR corresponding to the positive
wells, 24 individual PCR reactions were set up using 1 (or 2)
Vb and a mixture of 7 Jb primers. This allowed us to get a
specific band for 0–2 Vb which was then sequenced using
the relevant Vb primer. In 9 independent experiments car-
ried out on DN cells obtained from 3 different subjects, the
frequency of Va7-Ja331 wells ranged between 6 and 16/84.
Among the 92 Va7-Ja331 wells studied, a b chain could be
assigned and sequenced in 37 cases (40%), and we found that
there was a heavy bias toward Vb13 and Vb2. Out of 13 Vb
sequenced in donor A, 7 were BV131 and 3 were BV21. In
donor B, 8/12 were BV131 and 4/12 were BV21. In donor
C, 7/12 were BV131 and 2/12 were BV21. However, de-
spite this biased usage of BV13 or BV2 regions, the TCR b
chains derived from Va7-Ja331 cells did not show obvious
restrictions in Jb usage or in CDR3 length (Table I). Se-
quence analysis of VaJa junctions confirmed the presence of
Va7-Ja33 chains with the canonical CDR3 length and re-
vealed significant variations in amino acid composition at the
two N-encoded positions (Table I). Moreover, the presence
of repeated TCR a and b chain junctional sequences in dif-
ferent cells from the same subject cloned in different PCR
plates and the fact that these TCR chains were not found in
other subjects indicated that this subset had undergone clonal
expansion in vivo, an interpretation that is consistent with its
memory phenotype (see above). Overall, Va7-Ja331 cells
appear to use a semirestricted repertoire that is expanded as
needed.
TCR b Chain Repertoire of Va19-Ja331 Cells. Because the
frequency of Va19-Ja331 cells is not as high in mice as in
Figure 6. hAV7S2-AJ33–bearing cells are
CD8aa1 or DN. The indicated TCR a/b1
fractions were FACS® sorted using a four-
color staining with anti-CD4–TC, anti-
CD8a–FITC, anti-CD8b–PE, and anti-a/b
TCR–APC. The amounts of Ca (A) or
hAV7S2-AJ33 (B) transcripts were quanti-
fied by kinetic PCR using the ABI Prism
7700 apparatus (Taqman). This experiment
was repeated with cells from another subject
with identical results. DRn, difference in
fluorescence relative units.
Figure 5. mAV19-AJ331 cells
are more frequent in TAP2/2
mice. The indicated number of
DN T cells from B6 (A) or
TAP2/2 (B) mice were seeded
in PCR microplates, and the
presence of the mAV19-AJ33 re-
arrangement was detected by
PCR-ELISA.1914 A Novel T Cell Subpopulation in Mammals
humans, the strategy followed to characterize the surface
phenotype of human Va7-Ja331 cells was not successful in
mice. Therefore, to characterize the TCR b chain reper-
toire of this subset, we took advantage of the fact that
Va19-Ja331 cells are enriched in TAP2/2 mice (see be-
low). We generated T–T hybridomas from DN enriched
lymph node cells from TAP2/2 mice, and screened for ex-
pression of Va19-Ja33 transcripts. In agreement with the
single cell analysis (Fig. 5 B), 16/168 hybridomas studied
were Va19-Ja331. As shown in Table II, in all cases, these
hybridomas carried Va19-Ja33 chains with the canonical
CDR3 length and in all but two cases, the Va19-Ja33
junction was germline encoded. The Vb segments used
were predominantly BV81 (7/16) and BV61 (4/16). No
restriction in the Jb repertoire was apparent.
Development and Selection of Va7/19-Ja33–bearing Cells
Ontogeny of Va7/19-J33–bearing Cells. NK1 T cells are
not found in neonates and accumulate after birth (5).
Therefore, we examined cord blood lymphocytes for Va7/
19-Ja33 sequences by quantitative PCR and polyclonal se-
quencing of Va7-Ca or Va7-Ja33 amplicons on cDNA
obtained from enriched DN/CD81 or CD41 fractions.
We were unable to find significant amounts of invariant
Va7-Ja33 transcripts in cord blood in the six samples stud-
ied. However, significant amounts of this chain could be
obtained in young children, albeit in lower amounts than
in adults (data not shown).
Similarly, Va19-Ja33–bearing cells were not found in
spleen or thymus of mouse neonates (data not shown). They
were present in lymph nodes and blood in large amounts
and in smaller amounts in the spleen in the five mouse
strains tested, as shown in Table III (top), which displays a
summary of the studies examining the tissue distribution of
Table I. Vb Repertoire of Human Invariant AV7S2-AJ33
TCR a Chain–bearing Cells
Single TCR a/b1 DN T cells were FACS® sorted into 96-well PCR
plates. After screening for the presence of the invariant AV7S2-AJ33
chain, individual TCR a and b chains of the positive wells were char-
acterized and sequenced as described in Materials and Methods. The b
chain could be assigned for 40% of the wells. Three independent PCR
plates were studied for each subject, as indicated in the last column.
aSmall caps code for the recombination sequence signal.
b, c, d, eIdentical TCR a and b sequences probably representing a single
expanded clone.
fNot done.
Table II. Summary of the Mouse Vb Repertoire of T–T
mAV19-AJ331 Hybridomas
*In bold and underlined, N additions.1915 Tilloy et al.
Va19-Ja33–bearing cells. Importantly, although more than
half of the human invariant Va7-Ja331 cells were CD8aa1
cells, which might suggest an extrathymic development
pathway (43), invariant Va19-Ja33 rearrangements were
not detected in nude mice either by quantitative PCR (Ta-
ble III, top) or polyclonal sequencing (data not shown), in-
dicating that the thymus is required for their development.
Development of Va7-Ja331 Cells Is Not Affected in MHC
Class II– and TAP-deficient Patients. The restriction element
of Va7-Ja331 cells could be either a class I or class II
MHC molecule, as they do not express CD4 or CD8ab
accessory molecules. To address this issue, we quantified
the expression of the Va7-Ja33 invariant chain in PBLs
obtained from MHC-deficient patients. MHC class II–
deficient patients harbor low but significant numbers of
CD41  a/b lymphocytes whose Vb repertoire is grossly
normal (44). CD41, CD8a1, and DN enriched fractions
were prepared and analyzed by quantitative PCR. Al-
though the amount of Ca was much lower in the DN than
in the CD41 samples (Fig. 7 A), the amounts of Va7-Ja33
transcripts were comparable in both samples (Fig. 7 B),
therefore indicating an enrichment of Va7-Ja33 transcripts
within DN cells and, presumably, selection of invariant
Va7-Ja33–bearing cells in this patient. Accordingly, the
predominance of the invariant Va7-Ja33 sequence within
DN cells was confirmed by polyclonal sequencing (data not
shown). Similar results were obtained in the two other pa-
tients studied. Taken together, these results strongly suggest
that the restriction element of the invariant Va7-Ja331
cells is not an MHC class II molecule.
There is no MHC class I–deficient patient described to
date, but we could obtain PBLs from two TAP-deficient
siblings (45). In these patients, a/b1 TCR CD8a1 cells are
reduced in numbers at birth but may expand with age. a/b1
TCR CD41 and CD8a1 cells were separated in one of
these patients, and the amount of Ca and Va7-Ja33 tran-
scripts was quantified in the two fractions. Despite lower
amounts of Ca in the CD8a1 fraction, the amount of
Va7-Ja33 transcripts was much higher in the CD8a1 frac-
tion (Fig. 7, C and D). Enrichment for Va7-Ja33 tran-
scripts was also demonstrated in a PHA-stimulated CD8a1
line derived from the other TAP-deficient patient, when
compared with either unsorted PBL-derived cell line from
the same patient or to CD8a1 cells from healthy donors
(data not shown). Actually, the larger amounts of Va7-Ja33
transcripts in the CD8a1  a/b T cells of TAP-deficient
patients is in agreement with the higher proportion of
CD8aa1 cells in these patients (data not shown). This indi-
Table III. Strain and Tissue Distribution, and MHC Selection of mAV19-AJ331 T Cells
Strain Haplotype
Lymph
nodes Spleen PBLs Thymus
Bone
marrow Liver IELs
Lamina
propria
BALB/c H-2d 111 1 111 1 1 2 2 2
I-A1/I-E1
DBA/2 H-2d 111
I-A1/I-E1
CBA H-2k 111 1
I-A1/I-E1
129 H-2b 1 111
I-A1/I-E2
C57BL/6 H-2b 111 111 1
I-A1/I-E2
NUDE B6 H-2b 22
I-A1/I-E2
B6 I-Ab2/2 b2m2/2 Kb2/2/Db2/2 TAP2/2 CD12/2 CD82/2
mAV19-AJ33 11 11 2 11 111 11 11
(fold increase (2) (4) (8) (2) (4)
compared with B6)
mAV14-AJ18 11 11 2 11 11 2 11
DN a/b1/1 T cells were purified from the indicated organs in different mouse strains. Expression of the invariant mAV19-AJ33 TCR a chain was es-
timated by quantitative kinetic PCR and confirmed by polyclonal sequencing (see Materials and Methods, and Figs. 1 and 2). Tissue distribution results
are compared with the expression in sorted CD41 a/b1 T cells: 111, high expression (.3-cycle shift to the left); 1, no increase; 2, absence as
judged by polyclonal sequencing of mAV19-AJ33 amplicons. Selection results (bottom) in the lymph nodes of the different MHC-deficient mice are
compared with the expression in DN cells from B6 lymph nodes using quantitative PCR. All of the results were also confirmed by polyclonal sequenc-
ing after mAV19-Ca, or -AJ33 amplification as appropriate.1916 A Novel T Cell Subpopulation in Mammals
cates that T cells bearing this invariant a chain are probably
not selected by a TAP-dependent MHC class I molecule.
Thus, the selecting molecule for the invariant Va7-
Ja331 cells appeared to be neither an MHC class II nor a
classical MHC class I molecule. However, because the de-
fect in MHC class II expression may not be complete and
the level of MHC class I expression in TAP-deficient pa-
tients is still 1% of normal, no definitive conclusion could
be drawn from these studies. Therefore, we turned to the
mouse, where carefully controlled studies using well-char-
acterized MHC-deficient mice can be performed.
The Selecting Ligand for Va19-Ja331 Cells Is b2m-depen-
dent, TAP-independent, and Distinct from CD1. The amount
of Va19-Ja33 transcripts was examined in a/b1 DN lymph
node cells from several MHC-deficient strains. Because the
frequency of Va19-Ja331 cells and the percentage of DN
cells are lower in mice, the differences between positive and
negative samples are smaller in mice than in humans. How-
ever, despite higher levels of Ca in the b2m2/2 samples,
there were fewer Va19-Ja33 transcripts than in control or
I-Ab2/2 mice (Fig. 8, A and B). Polyclonal sequencing of
Va19-Ja33 amplicons from b2m2/2 samples showed the
complete absence of invariant Va19-Ja33 transcripts. This
was consistent with an MHC class I or b2m-dependent class
I–like selection of the invariant Va19-Ja331 cells. However,
the relevant molecule is not a classical MHC class I molecule
because the amount of invariant Va19-Ja33 transcripts was
higher in the DN cells from Kb2/2Db2/2 mice than in con-
trols, though the Ca levels were lower. These results suggest
that the MHC class I selecting molecule is not a classical one
and that, in the absence of classical class I molecules, the in-
variant chain–bearing DN cells are less diluted by main-
stream cells. In Fig. 8, C and D, Va19-Ja33 transcripts were
quantified in CD8-, CD1-, and TAP-deficient mice, B6 and
b2m2/2 mice being used as positive and negative controls,
respectively. There was no decrease in the amounts of
Va19-Ja33 transcripts in CD1-deficient mice, indicating
that Va19-Ja331 cells were not selected by CD1 or a CD1-
bound ligand. The curves for TAP2/2 samples were actually
shifted to the left, indicating an increased frequency of
Va19-Ja331 cells in TAP2/2 mice, in agreement with the
result shown in Fig. 5 B where the frequency of Va19-
Ja331 cells in DN TAP2/2 mice was 1/8.5 (i.e., a sixfold in-
crease compared with B6; Fig. 5 A). The Va19-Ja33 curve
corresponding to the CD8-deficient mice is similar to that of
B6, indicating the presence of Va19-Ja33 invariant chains in
CD82/2 mice. This was confirmed by polyclonal sequencing
(data not shown). Altogether, these results, summarized in
Table III (bottom), indicate that Va19-Ja331 cells do not
require CD8 for their selection and that the selecting mole-
cule is a b2m-dependent, TAP-independent molecule dis-
tinct from CD1.
Figure 7. AV7S2-AJ33–bearing cells are
present in MHC class II– and TAP-deficient
patients. The indicated cell subpopulations
were obtained from an MHC class II– (A
and B) or a TAP-deficient (C and D)
patient. The amounts of Ca or hAV7S2-
AJ33 transcripts were quantified by kinetic
PCR-ELISA. Two other MHC class II–
deficient patients and another TAP-deficient
patient were studied with similar results.1917 Tilloy et al.
Discussion
Invariant Va7.2-Ja33 TCR a chain and its murine and
bovine homologues were found in three different mamma-
lian species and, thus, define a new phylogenetically con-
served T cell population using a canonical TCR a reper-
toire. In humans, DN and CD8aa1 cells bearing invariant
Va7-Ja33 chain accumulate after birth and become quite
abundant, as they represent z0.1–0.2% of all human PBLs.
Therefore, it is legitimate to wonder why such cells have
not been previously reported. This may be due to the lack
of a stringent Vb repertoire restriction, or to the difficulties
in growing clones expressing this invariant chain (our un-
published observations), together with methodological lim-
itations linked to TCR a chain repertoire analysis (e.g.,
lack of allelic exclusion [46]). However, this invariant a
chain had already been described in DN cells by Porcelli et al.
(39) and, among the 317 random CDR3 sequences re-
ported by Moss and Bell (47), 4 (1.2%) had a sequence cor-
responding to the Va7-Ja33 invariant a chain. In the same
study, this canonical sequence was not found in cord blood
samples or in CD41 cells, but represented 3/40 (7.5%)
CDR3 sequences derived from CD8a1 cells. This age and
cell distribution is in agreement with our own measure-
ments (data not shown). In cattle, this CDR3 was found in
1/20 TCR a chains randomly sequenced (40). In mice,
random cloning of TCR a chains revealed one example of
this invariant Va19-Ja33 a chain (48). It should be stressed
that as shown in Fig. 3, the AJ33 segments are quasi-identi-
cal in the three species. The mouse and human Ja loci are
entirely homologous, with the same genomic organization
and an average similarity of 71% including the Ja coding
sequences (41, 42, 49). The AJ33 is the most similar Ja seg-
ment between mouse and human sequences with only one
amino acid difference; the two other most similar human/
mouse pairs (AJ23 and AJ24) have four and three amino
acid differences, respectively (41). This quasi identity be-
tween mouse and human AJ33 segments suggests a strong
selective pressure for these segments.
In humans and cattle, the TCR a chain displayed some
junctional diversity, whereas in mice a genomic sequence
without trimming or N additions was found in most cases
(Table II). However, a murine sequence made by trimming
and reconstitution of the canonical sequence through N
additions was found in two hybridomas (11F1 and 4H1 in
Table II), indicating that the TCR in mice is selected at the
protein level. In humans, the invariant TCR a chain was
associated with a limited number of Vb segments (mostly
hBV2 and hBV13), and the same TCR with the same nu-
cleotide sequence was present in different cells from two
subjects, suggesting oligoclonal expansions. Despite this
combinatorial restriction, TCR b chain diversity of invari-
ant Va7-Ja331 cells remained extensive, since most Jb seg-
ments and seven Vbs were found associated with CDR3s
of variable length. In mice, five different Vbs were ob-
served with a high proportion of mBV6 and mBV8. Im-
portantly, the murine orthologous segments of hBV13 are
mBV8 and mBV6 (50–52).
This semi-invariant repertoire selected at the protein
level is reminiscent of the repertoire observed in murine
epithelial DECs and in murine and human NK1 T cells. In
DECs, an invariant repertoire generated from genomic se-
quences is selected at the protein level, as the same epitope
recognizable by an mAb can be reconstituted by different
Vg segments when the original GV1 and GV2 segments
are inactivated by homologous recombination (13). For
NK1 T cells, selection at the protein level was also apparent
(14), and the transgenic overexpression of the invariant
mAV14AJ18 was sufficient to induce a large increase in the
number of NK1 T cells (53).
The restriction element of Va7/19-Ja331 cells is proba-
bly an MHC class Ib molecule distinct from CD1d, though
a b2m-derived peptide presented by a “nonclassical” class II
molecule cannot be formally excluded. The selecting mole-
cule should be present in both mice and humans. Murine
Qa-1 and human HLA-E might be good candidates, given
their structural homology and their ability to bind to ho-
mologous CD94/NKG2 receptors in both species (54–56).
However, when using HLA-E tetramers complexed with
HLA-G leader sequence–derived peptide (56), we were un-
able to find any difference in expression levels of the invari-
ant Va7-Ja33 a chain between FACS®-sorted HLA-E tet-
ramer–positive and –negative (DN plus CD8a1)  a/b1
TCR PBL fractions (data not shown). Moreover, the in-
Figure 8. AV19-AJ331 cells are selected by a b2m-dependent, TAP-
independent nonclassical MHC–like molecule distinct from CD1. DN
lymph node cells were obtained from the indicated mice, and the
amounts of Ca (A and C) and mAV19-AJ33 (B and D) transcripts were
quantified by kinetic PCR-ELISA. All results were confirmed by poly-
clonal sequencing.1918 A Novel T Cell Subpopulation in Mammals
variant Va19-Ja33 chain was not expressed by three TAP-
independent anti–Qa-1 clones provided by J. Forman
(University of Texas, Dallas, TX [57]; data not shown).
Nonetheless, no definitive conclusions as to the HLA-E/
Qa-1 specificity of the invariant TCR can be drawn from
these negative results because the invariant TCR may rec-
ognize HLA-E complexed with another peptide. Another
candidate class I molecule that is widely expressed in both
mice and humans is the recently described MR1 molecule
(58, 59). Identification of the selecting element is underway
by testing reactivity of mouse hybridomas against different
cell types and MHC class I/Ib transfectants.
The expression of CD8aa on Va7-Ja331 cells could ar-
gue for an extrathymic development pathway (43). How-
ever, these cells were not found in nude mice (Table III,
top), in human intraepithelial lymphocytes (IELs) (Cerf-
Bensussan, N., E. Treiner, and O. Lantz, unpublished re-
sults), or in murine IELs or lamina propria lymphocytes (Guy-
Grand, D., F. Tilloy, and O. Lantz, unpublished results), and
their frequency was not particularly high in mouse bone
marrow (Table III, top). Thus, Va7/19-Ja331 cells seem
to be mainly thymus dependent. In this respect, the fact that
we have been unable to find large numbers of these cells in
human or mouse thymus (data not shown) does not preclude
an intrathymic development. Indeed, if the antigen is not
present in sufficient amounts in the thymus, these cells may
not accumulate locally and may be diluted out by main-
stream a/b T cells in the periphery. The absence of signifi-
cant numbers of Va19-J331 cells in mouse CD8a1 cells
(Fig. 1 F, and polyclonal sequencing after V-J amplification
[not shown]) is in agreement with the extremely low num-
bers (,0.4%) of CD8aa1 cells in murine blood or lymph
nodes (data not shown). The CD8aa expression on some
invariant Va7-Ja331 cells and its complete absence on
Va19-Ja331 counterparts is reminiscent of the phenotype of
NK1 T cells, which may express CD8aa1 in humans (28)
but never in mice. The reasons for such phenotypic differ-
ences between mice/cattle and humans as well as the role of
CD8aa expression in human PBLs are not clear. There have
been contradictory reports concerning the role of homo-
versus heterodimeric CD8 (60–63). In addition, CD8aa ex-
pression in human PBLs might reflect an activated status
rather than a particular differentiation pathway (64).
Concerning the development pathway of the Va7/19-
Ja33 cells, in the three species there seems to be no expres-
sion of the invariant a chain in the CD8ab1 T cells, strong
enrichment for this sequence within DN cells (as well as
within human CD8aa1 cells), and persistence of the invari-
ant sequence in the CD41 subset. Indeed, in humans, the
frequency of invariant a chain–bearing cells was z1/6,000
in the CD41 fraction. Moreover, polyclonal sequencing
of Va7-Ja33 amplicons from CD41 cells (Fig. 2 A) revealed
the presence of canonical CDR3 at a low, though readable,
frequency, whereas the canonical CDR3 was undetectable in
CD8ab1 samples (Fig. 2 B). In mice and cattle, there was
also a small but reproducible shift of the CD41 amplification
curves to the left compared with the CD8a1 curves, suggest-
ing some expression of the invariant a chain in murine or bo-
vine CD41 cells. Accordingly, a readable canonical sequence
in Va19-Ja33 amplicons was detected in the CD41 but not
in the CD8a1 fraction in both species (data not shown). The
absence of any readable sequence after V-J amplification of
CD8a/b1 cells suggests that the CD8ab1 Va7/19-Ja33–
bearing cells are deleted by negative selection, as are NK1 T
cells in CD8 transgenic mice (14). These results are compati-
ble with the hypothesis that Va7/19-Ja33 cells follow a
normal T cell development pathway but that, in contrast
with NK1 T cells where the numbers of CD4 and DN
NK1 T cells are similar, CD41 T cells bearing the Va7/19-
Ja33 a chain are diluted out by mainstream lymphocytes.
A memory phenotype associated with an oligoclonal
repertoire may be related to recognition of either an en-
dogenous ligand or a ubiquitous pathogen. In favor of an
endogenous ligand is the finding that invariant Va7-Ja331
cells existed in an 18-mo-old child who had not been vac-
cinated with Calmette-Guérin bacillus (BCG) and in sev-
eral subjects who had negative EBV and CMV serologies
(data not shown). On the other hand, the abundance of
Va7/19-Ja33–bearing cells in humans and cattle contrast-
ing with a lower number of these cells in mice could be re-
lated to the clean environment in which laboratory mice
are housed. The two hypotheses are not mutually exclu-
sive, as cells selected by an endogenous ligand could be
ready to react against a highly prevalent pathogen.
Both NK1 T cells and Va7/19-Ja33–bearing cells dis-
play semi-invariant repertoires (i.e., one monomorphic a
chain and a biased Vb chain repertoire), suggesting that
their TCRs may have similar characteristics, probably a
high affinity for a selecting ligand by the invariant a chains,
as the transgenic overexpression of AV14AJ18 is sufficient
to greatly increase the number of NK1 T cells (53). To-
gether with the similarities in their restricting elements (a
TAP-independent,  b2m-dependent nonclassical MHC
class I–like molecule), the absence of accessory molecule
(CD4 or CD8) involvement suggests that they may recog-
nize a high-density ligand that might therefore be a saccha-
ride or a glycolipid.
Are there other invariant TCR a chains defining other T
cell subpopulations? We did not find any after measuring the
amounts of several other a chains which had been found ei-
ther in DN T cells (39) or in a “regulatory” subpopulation
(65–67; Tilloy, F., and O. Lantz, unpublished observations).
However, the definite resolution of this issue awaits a sys-
tematic study of the expression of all AV-AJ combinations,
and other populations may exist in other organs in the same
way that g/d subpopulations are distributed.
Concerning the functions of Va7/19-Ja331 lympho-
cytes, future analysis of the mAV19AJ33 transgenic mice
we have made will certainly help address this point. The
high frequency of Va7/19-Ja331 T cells and their exten-
sive phylogenetic conservation in mammals both argue for
an important physiological function. Because Va7/19-
Ja331 and NK1 T cells are selected by distinct ligands, they
may complement each other and act synergistically either
in defense mechanisms against broadly distributed patho-
gens or in immune/nonimmune homeostatic processes.1919 Tilloy et al.
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